Put company on watchlist
ABIVAX
ISIN: FR0012333284
WKN: A14UQC
About
Company Snapshot
New: Activate notification
Be informed about new publications
New: AI Factsheet

Coming soon: Summary of the company message by AI/p>

ABIVAX · ISIN: FR0012333284 · Newswire (Company)
Country: Frankreich · Primary market: France · EQS NID: 2107024
26 March 2025 22:05PM

 Abivax publishes financial reports with the French and U.S. securities regulatory agencies


EQS-News: ABIVAX / Key word(s): Annual Report
 Abivax publishes financial reports with the French and U.S. securities regulatory agencies

26.03.2025 / 22:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


 Abivax publishes financial reports with the French and U.S. securities regulatory agencies

PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025.

The Universal Registration Document includes the 2024 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

The documents will be available for download on the website of Abivax (www.abivax.com/investors), the AMF (www.amf-france.org), and the SEC (www.sec.gov/edgar).


About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.


Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878



26.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


2107024  26.03.2025 CET/CEST

smart.AD

Trading Solutions for Professionals

  • 25 kinds of clusters
  • 26 world exchanges
  • 14 different charts
  • 58 necessary for analysis indicators
  • 50+ customized templates for charts


Get your free Demo today

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Tuesday, 01.04.2025, Calendar Week 14, 91st day of the year, 274 days remaining until EoY.